Streetbeat News

Analyst Ratings

TWOU

BMO Capital analyst Jeffrey Silber maintains an Outperform rating on 2U (NASDAQ:TWOU) but lowers the price target from $9 to $6.

Portfolio Pulse from richadhand@benzinga.com

May 31, 2023 | 11:46 am

RBOT

Canaccord Genuity analyst Kyle Rose maintains a Buy rating on Vicarious Surgical (NYSE:RBOT) but lowers the price target from $12 to $9.

Portfolio Pulse from Benzinga Newsdesk

May 31, 2023 | 11:44 am

ZBH

Morgan Stanley analyst Cecilia Furlong maintains an Equal-Weight rating on Zimmer Biomet Holdings (NYSE:ZBH) and lowers the price target from $150 to $140.

Portfolio Pulse from Benzinga Newsdesk

May 31, 2023 | 11:41 am

SIBN

Morgan Stanley analyst Drew Ranieri maintains an Overweight rating on SI-BONE (NASDAQ:SIBN) and raises the price target from $27 to $30.

Portfolio Pulse from Benzinga Newsdesk

May 31, 2023 | 11:40 am

OM

Morgan Stanley analyst Drew Ranieri maintains an Equal-Weight rating on Outset Medical (NASDAQ:OM) and lowers the price target from $27 to $23.

Portfolio Pulse from Benzinga Newsdesk

May 31, 2023 | 11:39 am

NUVA

Morgan Stanley analyst Jonathan Demchick maintains an Equal-Weight rating on NuVasive (NASDAQ:NUVA) and lowers the price target from $43 to $40.

Portfolio Pulse from Benzinga Newsdesk

May 31, 2023 | 11:39 am

NVRO

Morgan Stanley analyst Cecilia Furlong maintains an Equal-Weight rating on Nevro (NYSE:NVRO) and lowers the price target from $40 to $29.

Portfolio Pulse from Benzinga Newsdesk

May 31, 2023 | 11:38 am

LYV

Morgan Stanley analyst Benjamin Swinburne maintains an Equal-Weight rating on Live Nation Entertainment (NYSE:LYV) and raises the price target from $80 to $90.

Portfolio Pulse from Benzinga Newsdesk

May 31, 2023 | 11:37 am

ISRG

Morgan Stanley analyst Cecilia Furlong maintains an Equal-Weight rating on Intuitive Surgical (NASDAQ:ISRG) and raises the price target from $285 to $310.

Portfolio Pulse from Benzinga Newsdesk

May 31, 2023 | 11:36 am

IART

Morgan Stanley analyst Drew Ranieri maintains an Equal-Weight rating on Integra Lifesciences (NASDAQ:IART) and lowers the price target from $59 to $43.

Portfolio Pulse from Benzinga Newsdesk

May 31, 2023 | 11:36 am